Dawnrays Pharmaceutical Holdings Ltd. announced that Ms. Huang Dongmei resigned as the Chief Executive Officer with effect from 1 March 2015; and (ii) Ms. Li Kei Ling was appointed as the Chief Executive Officer with effect from 1 March 2015. Ms. Li is also an executive director and the chairman of the Board of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.19 HKD | -0.83% | -1.65% | +13.33% |
03-26 | Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024 | CI |
03-25 | Dawnrays' 2023 Profit Falls 9% on Lower Revenue | MT |
1st Jan change | Capi. | |
---|---|---|
+13.33% | 231M | |
+38.69% | 728B | |
+33.13% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+15.77% | 244B | |
+7.87% | 207B | |
-5.40% | 205B | |
+6.42% | 164B |
- Stock Market
- Equities
- 2348 Stock
- News Dawnrays Pharmaceutical (Holdings) Limited
- Dawnrays Pharmaceutical Holdings Ltd. Announces Executive Changes, Effective March 31, 2015